Tell a Friend

Mohammad E Naffaa, Fadi Hassan, Avivit Golan-Cohen, Ilan Green, Amir Saab, Ziv Paz: Factors associated with drug survival on first biologic therapy in patients with rheumatoid arthritis: a population-based cohort study (Rheumatol Int . )

medicine shutterstock

Lack of sufficient head-to-head trials comparing biologic disease-modifying antirheumatic drugs (bDMARDs) in rheumatoid arthritis (RA), makes the choice of the first bDMARD a matter of rheumatologist's preference. Longer drug survival on the first bDMARD usually correlates with early remission. We aimed to identify factors associated with longer drug survival

Last Updated Date : 04/10/2021